Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

41.85
Delayed Data
As of Oct 20
 -0.75 / -1.76%
Today’s Change
17.25
Today|||52-Week Range
50.05
+65.74%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$2.1B

Company Description

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy. It also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Contact Information

Supernus Pharmaceuticals, Inc.
1550 East Gude Drive
Rockville Maryland 20850
P:(301) 838-2500
Investor Relations:
(301) 838-2522

Employees

Shareholders

Mutual fund holders54.42%
Other institutional44.09%
Individual stakeholders18.86%

Top Executives

Jack A. KhattarPresident, CEO, Secretary & Director
Gregory S. PatrickChief Financial Officer & Vice President
Padmanabh P. BhattChief Scientific Officer & Senior Vice President
Stefan K. F. SchwabeChief Medical Officer, EVP-Research & Development
Bryan A. RoeckleinVice President-Corporate Development